TARS vs. RVMD, LNTH, BPMC, BBIO, LEGN, ELAN, CYTK, NUVL, GRFS, and VKTX
Should you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Revolution Medicines (RVMD), Lantheus (LNTH), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Grifols (GRFS), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry.
Tarsus Pharmaceuticals vs.
Tarsus Pharmaceuticals (NASDAQ:TARS) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.
Revolution Medicines has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -103.64%. Revolution Medicines' return on equity of -33.67% beat Tarsus Pharmaceuticals' return on equity.
Revolution Medicines received 46 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. Likewise, 75.83% of users gave Revolution Medicines an outperform vote while only 65.22% of users gave Tarsus Pharmaceuticals an outperform vote.
Tarsus Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 8.0% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Tarsus Pharmaceuticals currently has a consensus price target of $54.20, suggesting a potential upside of 16.51%. Revolution Medicines has a consensus price target of $66.25, suggesting a potential upside of 64.43%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Revolution Medicines is more favorable than Tarsus Pharmaceuticals.
In the previous week, Tarsus Pharmaceuticals had 5 more articles in the media than Revolution Medicines. MarketBeat recorded 12 mentions for Tarsus Pharmaceuticals and 7 mentions for Revolution Medicines. Tarsus Pharmaceuticals' average media sentiment score of 0.60 beat Revolution Medicines' score of 0.26 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.
Tarsus Pharmaceuticals has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.
Summary
Revolution Medicines beats Tarsus Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get Tarsus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tarsus Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:TARS) was last updated on 1/20/2025 by MarketBeat.com Staff
